clinical trial · NCT06600321
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaALN-BCATPembrolizumab
brief summary
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
started
Dec 30, 2024
primary completion
Sep 30, 2027
completion
Oct 31, 2027
last updated
Jun 17, 2026
official title
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol